Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Ingrezza is a prescription vesicular monoamine transporter 2 inhibitor containing valbenazine. It is indicated for adults with tardive dyskinesia or chorea associated with Huntington disease. Standard and Sprinkle capsules are available in 40 mg, 60 mg, and 80 mg strengths.
read more about ingrezza ...Valbenazine reversibly inhibits vesicular monoamine transporter 2, which regulates movement of monoamines from the cell cytoplasm into synaptic vesicles for storage and release. Its exact therapeutic mechanism in tardive dyskinesia and Huntington chorea is not fully defined.
Ingrezza is used in adults with tardive dyskinesia or chorea associated with Huntington disease. Patients with Huntington disease are monitored closely for new or worsening depression, suicidal thoughts, or unusual behavior during treatment.
Tardive dyskinesia treatment starts at 40 mg once daily and increases after one week to 80 mg once daily. Huntington chorea treatment starts at 40 mg once daily and increases by 20 mg every two weeks to 80 mg once daily. Doses of 40 mg or 60 mg once daily are alternatives based on response and tolerability.
Ingrezza carries a boxed warning for depression and suicidal thoughts and behavior in patients with Huntington disease. Other serious concerns include hypersensitivity with angioedema, sedation, QT prolongation, neuroleptic malignant syndrome, and parkinsonism. Congenital long QT syndrome and arrhythmias associated with a prolonged QT interval are reasons to avoid treatment.
Ingrezza treats tardive dyskinesia and chorea associated with Huntington disease in adults.
The starting dose is 40 mg once daily for one week before an increase to 80 mg once daily.
Treatment starts at 40 mg once daily and increases by 20 mg every two weeks to 80 mg once daily.
Yes. The boxed warning concerns depression and suicidal thoughts and behavior in patients with Huntington disease.
INGREZZA (Valbenazine) Prescribing Information. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4c970164-cafb-421f-9eb5-c226ef0a3417. Date Accessed October 5, 2026.
KINECT 3: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Valbenazine for Tardive Dyskinesia. https://pubmed.ncbi.nlm.nih.gov/28320223/. Date Accessed October 5, 2026.
Safety and Efficacy of Valbenazine for the Treatment of Chorea Associated With Huntington's Disease (KINECT-HD): A Phase 3, Randomised, Double-Blind, Placebo-Controlled Trial. https://pubmed.ncbi.nlm.nih.gov/37210099/. Date Accessed October 5, 2026.
Valbenazine: MedlinePlus Drug Information. https://medlineplus.gov/druginfo/meds/a617023.html. Date Accessed October 5, 2026.
Valbenazine Therapy and CYP2D6 Genotype. https://www.ncbi.nlm.nih.gov/books/NBK609326/. Date Accessed October 5, 2026.